Serum samples for pharmacokinetic (PK) analysis were taken up to 24 h post-dose on Days 1, 8, and 29 in the post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF) phase 1/2, open-label, dose-escalation, multi-center study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered NS-018 in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF). NS-018 is an orally administered, selective, small molecule inhibitor of JAK2. In pre-clinical models, NS-018 is a potent and specific inhibitor of JAK2.

**TABLE 1.**

<table>
<thead>
<tr>
<th>JAK2i</th>
<th>Day 1</th>
<th>Day 8</th>
<th>Day 29</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ruxolitinib</td>
<td>4.5</td>
<td>2.7</td>
<td>322</td>
</tr>
<tr>
<td>Momelotinib</td>
<td>18</td>
<td>11</td>
<td>155</td>
</tr>
<tr>
<td>NS-018</td>
<td>6</td>
<td>0.72</td>
<td>33</td>
</tr>
</tbody>
</table>

**FIGURE 1.**

**RESUL TS**

**Safety**

- 82 patients were enrolled across the 12 dose cohorts.
- 20 patients at MTD, and 10 patients at MTD+1 were included in each cohort.
- No patients discontinued treatment due to AEs.
- 1 of 100 mg QD was observed for the recommended dose 2 dose level.

**Pharmacokinetics**

- 1 of 100 mg QD was observed for the recommended dose 2 dose level.
- 1 of 200 mg QD was observed for the recommended dose 2 dose level.
- 1 of 300 mg QD was observed for the recommended dose 2 dose level.

**Clinical Response**

- 100% Splenic clinical response was observed in 6/4 (15%) patients at 300 mg QD.

**REFERENCES**


**ACKNOWLEDGMENTS**

- The authors acknowledged the patients and their caregivers for their participation.

**DISCLOSURES**

- The authors have no relevant financial relationships to disclose.

- The authors have no relevant personal relationships to disclose.

- The authors have no relevant personal relationships to disclose.